NAS:HRTX (USA) Also trade in: Germany UK

Heron Therapeutics Inc

$ 17.81 -0.25 (-1.38%)
Volume: 980,072 Avg Vol (1m): 1,380,265
Market Cap $: 1.41 Bil Enterprise Value $: 1.13 Bil
P/E (TTM): 0.00 P/B: 4.22
Earnings Power Value -10.2
Net Current Asset Value 3.85
Tangible Book 4.23
Projected FCF -11.54
Median P/S Value 80.61
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 9/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 60.00
Cash-To-Debt ranked higher than
66.59% of 859 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
HRTX: 60
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.1, Med: 59.73, Max: 10000
Current: 60
0.1
10000
Equity-to-Asset 0.76
Equity-to-Asset ranked higher than
84.64% of 788 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
HRTX: 0.76
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -0.32, Med: 0.64, Max: 0.91
Current: 0.76
-0.32
0.91
Debt-to-Equity 0.02
Debt-to-Equity ranked higher than
82.05% of 596 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 31.22, Med: 0.32, Min: 0.01
HRTX: 0.02
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -2.49, Med: 0.27, Max: 2.95
Current: 0.02
-2.49
2.95
Debt-to-EBITDA -0.03
Debt-to-EBITDA ranked lower than
100.00% of 495 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 343059.67, Med: 1.92, Min: 0.01
HRTX: -0.03
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -0.31, Med: -0.02, Max: -0.01
Current: -0.03
-0.31
-0.01
Interest Coverage No Debt
Interest Coverage ranked lower than
100.00% of 648 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 2689668, Med: 86.08, Min: 0.01
HRTX: No Debt
Ranked among companies with meaningful Interest Coverage only.
N/A
Piotroski F-Score 5
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 4.62
DISTRESS
GREY
SAFE
Beneish M-Score 5.90
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -542.3%
WACC 6.77%

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -201.67
Operating Margin ranked lower than
91.26% of 801 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
HRTX: -201.67
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -13363.17, Med: -787.89, Max: -201.67
Current: -201.67
-13363.17
-201.67
Net Margin % -194.43
Net Margin ranked lower than
90.52% of 802 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
HRTX: -194.43
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -13537.37, Med: -718.56, Max: -194.43
Current: -194.43
-13537.37
-194.43
ROE % -58.05
ROE ranked lower than
92.43% of 832 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 316.96, Med: 5.94, Min: -3119.47
HRTX: -58.05
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -359.44, Med: -127.07, Max: -58.05
Current: -58.05
-359.44
-58.05
ROA % -45.95
ROA ranked lower than
92.77% of 871 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
HRTX: -45.95
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -168.65, Med: -98.37, Max: -45.95
Current: -45.95
-168.65
-45.95
ROC (Joel Greenblatt) % -529.19
ROC (Joel Greenblatt) ranked lower than
92.98% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
HRTX: -529.19
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -4196.41, Med: -2017.89, Max: -529.19
Current: -529.19
-4196.41
-529.19
3-Year Total EBITDA Growth Rate -22.10
3-Year EBITDA Growth Rate ranked lower than
76.85% of 704 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 299.6, Med: 7.3, Min: -343.2
HRTX: 6.3
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -116.6, Med: -3.2, Max: 70.5
Current: 6.3
-116.6
70.5
3-Year EPS w/o NRI Growth Rate 6.10
3-Year EPS w/o NRI Growth Rate ranked lower than
72.70% of 663 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 385.8, Med: 8.9, Min: -403.2
HRTX: 6.1
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -8.3, Max: 62.5
Current: 6.1
0
62.5

» HRTX's 30-Y Financials

Financials (Next Earnings Date: 2019-08-08)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:HRTX

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS : 325412    SIC : 2834
Compare NAS:ENDP HKSE:02616 SZSE:000078 TSX:APHA BOM:524494 NAS:SUPN NAS:IRWD SZSE:300630 TSE:4521 SHSE:603567 NAS:TCDA SHSE:600267 NAS:PCRX SZSE:000650 SZSE:300725 TSX:HEXO SZSE:300194 SHSE:600216 SHSE:600329 XSWX:SFZN
Traded in other countries AXD2.Germany 0J4V.UK
Address 4242 Campus Point Court, Suite 200, San Diego, CA, USA, 92121
Heron Therapeutics Inc is a biotechnology company, developing products to address unmet medical needs. It is developing novel, patient-focused solutions that apply its science and technologies to already-approved pharmacological agents.

Ratios

Current vs industry vs history
PB Ratio 4.22
PB Ratio ranked lower than
83.64% of 819 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 227.39, Med: 2.64, Min: 0.05
HRTX: 4.22
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 1.27, Med: 8.86, Max: 139.56
Current: 4.22
1.27
139.56
PS Ratio 14.08
PS Ratio ranked lower than
92.26% of 775 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
HRTX: 14.08
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 3.17, Med: 63.68, Max: 465.15
Current: 14.08
3.17
465.15
EV-to-EBIT -5.98
EV-to-EBIT ranked lower than
100.00% of 572 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
HRTX: -5.98
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -25.2, Med: -5, Max: 4.7
Current: -5.98
-25.2
4.7
EV-to-EBITDA -6.01
EV-to-EBITDA ranked lower than
100.00% of 597 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
HRTX: -6.01
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -25.5, Med: -5.1, Max: 5
Current: -6.01
-25.5
5
EV-to-Revenue 11.54
EV-to-Revenue ranked lower than
91.57% of 795 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
HRTX: 11.54
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: -14, Med: 121.45, Max: 1458.3
Current: 11.54
-14
1458.3
Current Ratio 4.40
Current Ratio ranked higher than
83.63% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
HRTX: 4.4
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.89, Med: 4.18, Max: 14.23
Current: 4.4
0.89
14.23
Quick Ratio 4.06
Quick Ratio ranked higher than
84.44% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
HRTX: 4.06
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.64, Med: 4.12, Max: 14.23
Current: 4.06
0.64
14.23
Days Inventory 275.52
Days Inventory ranked lower than
95.89% of 755 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
HRTX: 275.52
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 275.52, Med: 614.49, Max: 27844.29
Current: 275.52
275.52
27844.29
Days Sales Outstanding 277.03
Days Sales Outstanding ranked lower than
96.88% of 770 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
HRTX: 277.03
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 30.86, Med: 304.59, Max: 559.34
Current: 277.03
30.86
559.34
Days Payable 100.30
Days Payable ranked higher than
80.87% of 758 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
HRTX: 100.3
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 100.3, Med: 1504.95, Max: 81895.57
Current: 100.3
100.3
81895.57

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -26.60
3-Year Share Buyback Rate ranked lower than
83.89% of 571 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 100, Med: -5.3, Min: -815
HRTX: -26.6
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -127.2, Med: -10.6, Max: 0
Current: -26.6
-127.2
0

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 4.21
Price-to-Tangible-Book ranked lower than
77.04% of 749 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 972.22, Med: 3.33, Min: 0.05
HRTX: 4.21
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 1.35, Med: 6, Max: 67.65
Current: 4.21
1.35
67.65
Price-to-Median-PS-Value 0.22
Price-to-Median-PS-Value ranked higher than
63.12% of 743 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
HRTX: 0.22
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.04, Med: 0.17, Max: 6.24
Current: 0.22
0.04
6.24
Earnings Yield (Joel Greenblatt) % -16.75
Earnings Yield (Greenblatt) ranked lower than
80.28% of 867 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
HRTX: -16.75
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -26424.9, Med: -19.4, Max: 5351
Current: -16.75
-26424.9
5351

More Statistics

Revenue (TTM) (Mil) $ 97.51
EPS (TTM) $ -2.46
Beta 0.71
Volatility % 35.66
52-Week Range $ 16.2 - 42.9
Shares Outstanding (Mil) 79.19

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 5
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y